The results highlight the importance of evaluating and monitoring cognitive function in individuals with recent critical illness or major infections, especially if they are already at risk for dementia.
Low-dose naproxen increases frequency of adverse health effects and does not reduce progression of presymptomatic Alzheimer disease in cognitively intact persons at risk.
Use of the orally administered β-site amyloid precursor protein-cleaving enzyme 1 inhibitors, verubecestat and atabecestat, does not prevent clinical progression to Alzheimer disease.
Gerontologists, practicing ethicists, policymakers, and health practitioners should consider the structural conditions of long-term care that both foster aggression and constrain prevention efforts, according to this commentary.
Avanir announced data from the phase 3 clinical program that evaluated AVP-786 (deudextromethorphan hydrobromide/quinidine sulfate) for the treatment of moderate-to-severe agitation in patients with Alzheimer dementia.
Memantine monotherapy was associated with a 7% lower risk for any cardiovascular event compared with both acetylcholinesterase inhibitor monotherapy and combination therapy, according to a new study.
